ABUS icon

Arbutus Biopharma
ABUS

Overview Fund Activity

50 hedge funds and large institutions have $133M invested in Arbutus Biopharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 5 closing their positions.

Holders
50
Holders Change
-3
Holders Change %
-5.66%
% of All Funds
1.25%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
3
Increased
18
Reduced
16
Closed
5
Calls
$483K
Puts
$189K
Net Calls
+$294K
Net Calls Change
+$363K

Top Buyers

1
RI
1
RTW Investments
New York
$18.8M
2
Victory Capital Management
2
Victory Capital Management
Texas
$478K
3
Renaissance Technologies
3
Renaissance Technologies
New York
$757K
4
Deutsche Bank
4
Deutsche Bank
Germany
$653K
5
OAM
5
Oxford Asset Management
United Kingdom
$300K

Top Sellers

1
AC
1
Armistice Capital
New York
$0
2
AWG
2
Alpha Wave Global
New York
$0
3
SM
3
Sabby Management
Florida
$895K
4
Goldman Sachs
4
Goldman Sachs
New York
$330K
5
Jennison Associates
5
Jennison Associates
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
Jennison Associates
51
Jennison Associates
New York
– -$455K -140,019 Closed
Millennium Management
52
Millennium Management
New York
– -$149K -45,818 Closed
WS
53
Wedbush Securities
California
– -$59K -18,045 Closed
1 2
3